Growing Incidences of Neurodegenerative Conditions to Boost Market Growth for Neurodegenerative Drugs

Published Date : Mar 14, 2017

ALBANY, New York, March 14, 2017: has announced the addition of a new market research report to its report repository. The publication is titled, “Global Neurodegenerative Drugs Market To 2022 - Growth Driven By An Aging Population, The Approval Of Novel Immunomodulators And Neuromodulators, And Strong Uptake Of Marketed Anti-Inflammatory Treatments.” The study examines the growth of the market followed over the last few years and the prospects of growth in the near future. The research report details out the causes accountable for the variations in the market and analyses them thoroughly. The impact of certain trends has also been discussed in the report. It further provides data on the market shares, strategies, and products of leading companies. 

Neurodegenerative conditions are a bunch of disorders that impact the central nervous system. These conditions comprise both sporadic and hereditary conditions that are categorized by irreversible, slow, and progressive non-functioning of the nervous system with the swelling deterioration of neurons, which sources the symptoms such as diminishing cognitive ability, motor impairment, and memory loss. At present, neurodegenerative disorders cannot be cured, and the treatment is focused at handling the disease symptom in order to decrease the sternness of symptoms and slowdown the progression. 

The report puts emphases on five prime signs within neurodegenerative disorders: Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, multiple sclerosis, and amyotrophic lateral sclerosis. With no remedial therapies available, indicative medications recommended off-label are an imperative part of the treatment standard, particularly in multiple sclerosis and amyotrophic lateral sclerosis. This specifies the need for broad research and development within this field. 

For Sample Copy, click here: 

Immunomodulators are the utmost operative and common therapies employed in neurodegenerative ailments. This group of compounds were commercially fruitful in the previous decade, mainly in the multiple sclerosis market, with numerous clinical trials arranged for amyotrophic lateral sclerosis. The neurodegenerative disorders market is mainly comprised of premium products, with basic products holding only a comparatively small share. Nevertheless, some standard products have been able to account for substantial market shares after the patent expiries of important drugs. Glatopa (a generic version of Copaxone) lately entered the market and is anticipated to touch a sales of $233m during the forecast period. 

Although there is a greater degree of disappointment and doubt within the research and development of neurodegenerative disorder drugs, the amount of drugs in the pipeline is very high being around 1,494. The bulk of pipeline products are original active pharmaceutical components, with only a small proportion of produces being either standard or relocated from other indications. This displays evolution in terms of the diversity of molecules being advanced as therapeutic agents in the neurodegenerative disorders pipeline. The market is anticipated to progress over the forecast period, which is ascribed to the authorization of new drugs, as well as the growing aging population. 

To order report Call Toll Free: 866-997-4948 or send an email on